---
title: "AI pharmaceutical company InSilico Medicine Cayman TopCo is racing for a Hong Kong IPO, with its core product having received approval from China's CDE to commence Phase III clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265300194.md"
description: "The AI biotechnology company InSilico Medicine Cayman TopCo has updated its Hong Kong IPO prospectus, expecting revenue of USD 85.83 million in 2024, a year-on-year increase of 67.7%, with an adjusted net loss of USD 22.67 million, significantly narrowing compared to the previous year. The company's cash and cash equivalents are expected to increase from USD 126 million at the end of 2024 to USD 212 million by the end of June 2025. Its core product ISM001-055 (Rentosertib) has been confirmed by China's CDE to proceed with Phase III clinical trials"
datetime: "2025-11-11T09:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265300194.md)
  - [en](https://longbridge.com/en/news/265300194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265300194.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265300194.md) | [繁體中文](https://longbridge.com/zh-HK/news/265300194.md)


# AI pharmaceutical company InSilico Medicine Cayman TopCo is racing for a Hong Kong IPO, with its core product having received approval from China's CDE to commence Phase III clinical trials

Today, AI biotechnology company InSilico Medicine updated its Hong Kong IPO prospectus. In 2024, the company’s revenue is expected to be USD 85.83 million, a year-on-year increase of 67.7%; the adjusted net loss is expected to be USD 22.67 million, significantly narrowing year-on-year. Benefiting from the Series E financing completed in the first half of 2025, the company’s cash and cash equivalents increased from USD 126 million at the end of 2024 to USD 212 million by the end of June 2025.

Its core product ISM001-055 (Rentosertib) has received confirmation from China’s CDE to proceed with Phase III clinical trials after successfully completing Phase IIa studies in China. (Hard AI)

## Related News & Research

- [Meet 'Dobby': The AI agent that could kill the app economy](https://longbridge.com/en/news/281354277.md)
- [InSilico Medicine Boosts AI Platform and Advances Clinical Pipeline](https://longbridge.com/en/news/280916373.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [Letter from the Editor Introducing AI Intelligence on American Banker](https://longbridge.com/en/news/281266312.md)
- [NVIDIA'S AI ACCELERATOR MARKET SHARE IN CHINA DROPS IN 2025.](https://longbridge.com/en/news/281355484.md)